Vaccine Based on Recombinant Fusion Protein Combining HBV PreS with SARS-CoV-2 Wild-Type- and Omicron-Derived RBD Strongly Induces Omicron-Neutralizing Antibodies DOI Open Access
Pia Gattinger, Bernhard Kratzer, Al Nasar Ahmed Sehgal

et al.

Published: Jan. 16, 2024

Background: COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a recurrent endemic disease affecting whole world. Since November 2021, Omicron and its subvariants are dominating. In order to prevent courses of disease, vaccines needed boost maintain antibody levels capable neutralizing Omicron. Recently we produced characterized SARS-CoV-2 vaccine based on recombinant fusion protein consisting hepatitis B virus (HBV)-derived PreS two wild-type RBDs. Objectives: To develop PreS-RBD which induces high Omicron-specific antibodies. Methods: We designed, produced, compared strain-specific (wild-type: W-PreS-W; Omicron: O-PreS-O), bivalent (mix W-PreS-W O-PreS-O) chimeric (i.e., W-PreS-O) subunit vaccines. Immunogens were in vitro chemical methods, mass-spectrometry, circular dichroism combination with thermal denaturation immunological methods. addition, BALB/c mice immunized aluminum hydroxide-adsorbed proteins hydroxide alone placebo) study specific cytokine responses, safety neutralization. Results: Defined pure immunogens could be large amounts as secreted folded mammalian cells. Antibodies induced after vaccination different doses strain-specific, reacted RBD dose-dependent manner resulted mixed Th1/Th2 immune response. Interestingly, RBD-specific IgG comparable but W-PreS-O-induced neutralization titers against (median VNT50: 5000) 7- 2-fold higher than W-PreS-W- O-PreS-O-specific ones, respectively 6-fold those vaccine. Conclusion: Among tested immunogens, vaccine, W-PreS-O, highest Thus, W-PreS-O seems highly promising candidate for further preclinical clinical evaluation.

Language: Английский

Vaccine Based on Recombinant Fusion Protein Combining HBV PreS with SARS-CoV-2 Wild-Type- and Omicron-Derived RBD Strongly Induces Omicron-Neutralizing Antibodies DOI Open Access
Pia Gattinger, Bernhard Kratzer, Al Nasar Ahmed Sehgal

et al.

Published: Jan. 16, 2024

Background: COVID-19 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a recurrent endemic disease affecting whole world. Since November 2021, Omicron and its subvariants are dominating. In order to prevent courses of disease, vaccines needed boost maintain antibody levels capable neutralizing Omicron. Recently we produced characterized SARS-CoV-2 vaccine based on recombinant fusion protein consisting hepatitis B virus (HBV)-derived PreS two wild-type RBDs. Objectives: To develop PreS-RBD which induces high Omicron-specific antibodies. Methods: We designed, produced, compared strain-specific (wild-type: W-PreS-W; Omicron: O-PreS-O), bivalent (mix W-PreS-W O-PreS-O) chimeric (i.e., W-PreS-O) subunit vaccines. Immunogens were in vitro chemical methods, mass-spectrometry, circular dichroism combination with thermal denaturation immunological methods. addition, BALB/c mice immunized aluminum hydroxide-adsorbed proteins hydroxide alone placebo) study specific cytokine responses, safety neutralization. Results: Defined pure immunogens could be large amounts as secreted folded mammalian cells. Antibodies induced after vaccination different doses strain-specific, reacted RBD dose-dependent manner resulted mixed Th1/Th2 immune response. Interestingly, RBD-specific IgG comparable but W-PreS-O-induced neutralization titers against (median VNT50: 5000) 7- 2-fold higher than W-PreS-W- O-PreS-O-specific ones, respectively 6-fold those vaccine. Conclusion: Among tested immunogens, vaccine, W-PreS-O, highest Thus, W-PreS-O seems highly promising candidate for further preclinical clinical evaluation.

Language: Английский

Citations

1